For eligibility in this NMA, studies were required to meet specific criteria: (1) They had to be Phase II or III RCTs concentrating on cases diagnosed with histologically or cytologically confirmed EGFR mutation-positive advanced NSCLC at stage III, IV, or relapsed stage (patients with advanced NSCLC who have relapsed after previous radical treatment); (2) RCTs comparing a minimum of two first-line therapies, at least one of which included an EGFR-TKI; and (3) RCTs that reported at least one outcome, including OS or PFS. Here, EGFR is linked to non-small cell lung carcinoma.